Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform

12/09/21 Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled “The Methods and Composition for Gene Delivery Using an Engineered Viral Particle.”

Read More >